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Purpose: In Sturge–Weber disease, motor and cognitive defects are supposed to result mostly from severe epilepsy. They might,
therefore be partly prevented by prophylactic antiepileptic drug treatment. This condition constitutes a possible model for the
study of prophylactic drug treatment in severe epilepsy. In the present study, we compared the outcome of patients treated
prospectively with phenobarbitone before the first seizure, with those referred following the first seizure, in order to identify the
issues related to the evaluation of prophylactic treatment of severe epilepsy.
Methods: Motor and cognitive outcome were compared in patients treated prophylactically with phenobarbitone (16 cases) and
in those treated following the first seizures (21 cases).
Results: Whereas the incidence of motor deficit was similar in both groups (44 vs. 52%), that of mental retardation was lower
in the group treated prophylactically (76.2 vs. 43.7%, P < 0.05). The major methodological issues encountered included the
small number of patients identified at birth that could be included in the study, the need for randomization taking into account
the size of the angioma, and the choice of the prophylactic medication, including the occurrence of epilepsy together with the
course of motor and cognitive functions among the endpoints.
Conclusion: Prophylactic anti-epileptic drug treatment is worth considering for Sturge–Weber disease, but a randomized prospec-
tive study is necessary to determine this. It should be multicentric, take in account the size of the angioma, and decide what the
most appropriate medication should be.
c© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved
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INTRODUCTION
Although the mechanisms of intractability of epilepsy
remain poorly understood, there is growing evidence
that it affects certain categories of patients from the
very beginning of the first seizure disorder1. Pre-
vention of the first seizure by prophylactic treatment
could be one means of avoiding an intractable course,
for conditions in which a high risk of intractability
can be identified before the occurrence of the first
seizure. However, such an unusual concept is likely
to raise methodological difficulties that have not been
addressed to date.
Sturge–Weber disease (SW)2 is one of those rare
conditions in which a high risk of intractable and
devastating epilepsy can be predicted before the
occurrence of any seizure. Indeed, it combines a
facial port-wine stain over the area of the first branch
of the trigeminal nerve (V1) that can be identified
from birth, and the ipsilateral leptomeninges that is
responsible for the severe epilepsy that affects 80%
of the children3. Choroid angiomas may also be
observed. Epilepsy usually starts very early in life and
often comprises prolonged convulsions as the initial
manifestation, followed by frequent intractable and
disabling seizures4, 5.
Mental retardation and motor deficits (that respec-
tively affect 60% and 50% of patients) follow the onset
of epilepsy4–6. Therefore, controlling epilepsy is a
major aspect of treatment. Ideally, treatment should
prevent the first seizures since they are likely to
be devastating. In this perspective, Gilly et al., and
Salman6, 7 proposed treating ‘before the onset of the
seizures in the newborn with facial port wine stain’
α associated pial angioma. They proposed to identify
suitable cases on the basis of ‘reduced cortical activity
on EEG and/or abnormal cerebral scintography’.
From 1978, we applied this concept of prophylactic
treatment prospectively in the Neuropaediatric De-
partment of Saint Vincent de Paul Hospital, treating
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from birth all the patients with SW disease identified
on the basis of a typical port-wine stain in the
V1 location. Since, at that date, phenobarbitone
was the only anticonvulsant compound available
for the neonatal period, this drug was selected for
prophylactic treatment. The purpose of the present
study was to compare the outcome of patients treated
before the onset of seizures with those referred before
1978 and treated after the first seizure.
PATIENTS AND METHODS
We compared the 16 patients who, from 1978 to
1996, received phenobarbitone prospectively before
any seizure to the 21 who had been referred to
our department following first seizures, before 1978.
All 37 children were born between 1969 and 1994
and had been referred to Saint-Vincent de Paul
Hospital for SW disease. SW disease was suspected
on the basis of the topography of the port-wine
stain in the V1 area, the presence of glaucoma
and/or neurological manifestations, and confirmed
by brain imaging, computed tomography scan (CT)
and/or magnetic resonance imaging (MRI)8. We also
included three children for whom a pial angioma was
demonstrated on brain imaging although they had no
facial angioma. Follow-up was at least 2 years.
For the whole series, we studied the characteristics
of facial angioma, ocular manifestations, character-
istics of the epilepsy, psycho-motor development,
motor defects and the results of neuroimaging and
neurophysiological investigations.
We then compared both groups, whether treated
or not before the first seizures, in terms of char-
acteristics of their epilepsy, occurrence of mental
retardation, and of motor deficits. Regarding epilepsy,
we considered age of onset, seizure characteristics,
pharmacoresistance, occurrence of prolonged seizures
lasting for more than 1 hour, and age at last seizure,
or the age from which the child was having less than
one seizure every other month. Pharmacoresistance
was defined by the occurrence of more than one
seizure a month with appropriate treatment. Age
at seizure control was defined as that from which
the child had less than one seizure every other
month. For psychomotor development, children were
considered as severely retarded when their intelligence
quotient (IQ) was under 50, moderately delayed when
IQ was between 50 and 80, and having normal
development when IQ was over 80 or considered
normal by the physician and those caring for the
child at school. Motor deficit was graded as severe
in the case of hemiplegia or hemiparesis with major
muscle weakness, moderate in the case of inability to
perform fine finger movements, and mild when there
was discrete asymmetry between both sides or mild
clumsiness in fine movements.
The same comparison between both groups was then
performed according to the size of the angioma. On CT
and/or MRI, we could distinguish extensive angiomas
that affected more than one lobe or was bilateral, from
localized angiomas that were restricted to one lobe.
RESULTS
1. Findings regarding the overall series
In the overall series combining both groups, there
was a slight male predominance with 21 males to
16 females. Age at the end of follow-up ranged from
2 years 9 months to 28 years. There was no neonatal
injury or family history of epilepsy or SW disease. All
children but three had a facial port-wine stain in the
area of V1. Other localization’s could be associated
(V2, V3, the limbs, trunk. . .) without any correlation
between the size of the facial port-wine stain and
the size of the pial angioma. All children had a pial
angioma diagnosed on CT (atrophy, visualization of
the angioma, calcifications, hypertrophy of the choroid
plexus) and/or the MRI (atrophy, visualization of the
angioma, accelerated myelination).
The angioma was small in 22 children and extensive
in 15. Apart from the Klippel–Trenaunay syndrome in
two children, there were no other abnormalities.
Epilepsy
Thirty two (85%) children had epilepsy. The mean age
of onset of the seizures was 8 months (0.1 month–
3 years). Only three (10%) children had their first
seizure after the age of one year, and only one of them
after the age of two.
Epilepsy was considered as severe in 18 patients
(56.2%). Seventeen (53%) had at least one prolonged
seizure. Eight of these 17 (47%) exhibited a motor
deficit after the prolonged seizure. In addition, one
patient had a prolonged seizure in the course of
meningitis. The age of the first prolonged seizure was
known for 14 children, and it initiated the seizure
disorder for eight of them (57%). Occurrence of a
prolonged seizure was associated with severe epilepsy
in all cases except three. Of the 18 children with severe
epilepsy, only four had never had a prolonged seizure.
Therefore there was a significant relation between the
occurrence of prolonged seizures and further severe
epilepsy (P < 0.05).
The characteristics of the seizures were clearly
identified for 28 children. They were generalized
in three and partial in 25, of whom eight were
complex partial, and three most often secondarily
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Table 1: Correlation between the occurrence of epilepsy and neurological outcome.
Total Epilepsy No
Epilepsy
Patients 37 32 5
Normal development 14 (37.8%) 10 (31.2%) 4 (80%)
Mental retardation 23 (62%) 22 (68.7%) 1 (20%)
—Moderate 14 (37.8%) 13 (40.6%) 1 (20%)
—Severe 9 (24.3%) 9 (28.1%) 0
Motor deficit 18 (48.6%) 17 (53.1%) 1 (20%)
—Hemiplegia 3 3 0
—Moderate 2 2 0
—Mild 13 12 1
generalized. Five children had in addition other kinds
of seizures. Of the three children with only generalized
seizures, one had infantile spasms, one atonic, and
one, tonic seizures. Despite their young age when
starting epilepsy, only two children had exhibited
infantile spasms in the course of the disorder.
At the last visit, epilepsy remained uncontrolled for
only five children, aged 5, 9, 10, 12 and 18 years.
For eight other children, epilepsy had been stabilized,
with therefore less than one seizure every other month,
since the mean age of 6.1 years. Nineteen patients
were completely seizure free from the mean age of
5.4 years. Surgery was performed in four patients and
consisted of hemispherotomy in three, respectively at
the ages of 3, 5 and 20 years, and all three became
seizure free. One had had a callosotomy at the age of
11 that failed to totally control the seizures. Therefore,
cessation of seizure occurred in the majority of
the cases independently of surgery, and the risk of
recurrent seizures seems to decrease strongly by the
end of the first decade.





Normal development 8 (57.1%) 2 (11.1%)
Mental retardation 6 (42.9%) 16 (88.8%)
—Moderate 4 (28.6%) 9 (50%)
—Severe 2 (14.3%) 7 (38.8%)





The findings are summarized in Tables 1 and 2.
Twenty-three (63%) children suffered mental
retardation, which was severe in nine (23%). The
percentage of mental retardation was greatly increased
by the occurrence of epilepsy, especially when the
latter was severe.
Motor deficits affected 16 (48.6%) patients, it
mostly mildly, but were more severe in patients with
epilepsy.
2. Comparison between groups receiving or not
prophylactic treatment
Epilepsy
The findings are shown in Table 3. Five of the
16 children (31%) with prophylactic treatment re-
mained free of seizures whereas there were none in
the group without prophylactic treatment. Epilepsy
started significantly later for children who received
prophylactic treatment than for those who did not.
There was a trend towards less severe epilepsy, with
less prolonged seizures.
Psycho-motor development
Findings are shown in Table 4: about half the patients
exhibited less mental retardation in the population
with prophylactic treatment than in that without.
Severity of mental retardation tended to be milder in
the group with prophylactic treatment.
Motor deficit
Findings are listed in Table 5. The percentage of motor
deficit was similar in both groups.
3. Findings according to the size of the angioma
The size of the angioma was evaluated based on
leptomeningeal enhancement after Gadolinium R©,
atrophy and calcifications visible on CT scan or
MRI (Table 6). Fifty percent of the children without
prophylactic treatment had an extensive pial angioma
compared to only 25% in the population treated before
the onset of seizures.
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Existence of seizures 11 21 P < 0.01
Mean age of onset 11.2 months (1–36) 6.4 months (0.1–21) P < 0.05
Prolonged seizures 5 (31.2%) 12 (57.2%) NS
Severe epilepsy 5 (31.2%) 13 (61.9%) NS




Normal development 9 (56.2%) 5 (23%) P < 0.05
Mental retardation 7 (43.7%) 16 (76.2%)
—Moderate 5 (31.2%) 9 (42.8%) NS
—Severe 2 (12%) 7 (33%) NS
The findings show that 73% of the children with an
extensive angioma had severe epilepsy compared to
only 32% in the population with a localized angioma;
87% of the cases with extensive angioma were men-
tally retarded, severely for 60% of them, compared
to only 45% with mental retardation and no case of
severe mental retardation when the pial angioma was
localized; likewise, motor deficit affected 80% of the
children with extensive angioma, compared to only
27% when the pial angioma was small.








There was no statistical difference within each
subgroup by size of the angioma, regarding the
incidence of epilepsy, mental retardation and motor
deficit. However, there was a trend towards less
severity of epilepsy and less mental retardation in the
subgroups with prophylactic treatment.
DISCUSSION
The present study is the first to evaluate the impact
of prophylactic antiepileptic drug treatment, in a
selected paediatric population with high risk of severe,
deleterious and refractory epilepsy. As with every first
approach to a new concept, it faced methodological
problems, which should be resolved in future studies.
The most important was the absence of randomization
of the two groups, which introduced both predictable
and unpredictable bias. Although this study does
not permit any definitive conclusion regarding the
potential benefit of prophylactic antiepileptic drug
treatment in SW disease, it provides arguments strong
enough to convince patients and physicians of the
necessity of a randomized study addressing this issue.
In the present series, the incidence of epilepsy was
higher in the non-treated group (100%) than in those
receiving prophylactic treatment (69%). In addition
to any beneficial effect of treatment preventing the
occurrence of epilepsy, two other reasons could
account for this difference: (1) the fact that patients in
the non-treated group had been referred for epilepsy
but not those in the prophylactically treated group,
(2) the fact that the size of the angioma was smaller
in the non-treated group is another bias since the
occurrence of seizures in SW disease is related to
the size of the angioma4, 9. Nevertheless, 31% of
the patients treated prophylactically did not develop
seizures whereas this is the case in no more than 20%
in non-selected series3, 4, 6.
In the present series, there was a contrast between
motor function being similar in both groups, and cog-
nitive function being clearly better in the prophylacti-
cally treated group. Motor and cognitive defects could
result either from the seizures or from necrotic lesions
due to the angioma10–12. Epilepsy has been shown
to be a factor leading to worsening cerebral function
in SW syndrome: indeed, regional cerebral blood
flow (rCBF) measured in the area of the angioma
using SPECT (single-photon emission computed to-
mography) is decreased after the first seizure, whereas
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Table 6: Evolution according to prophylactic treatment and size of the angioma.
Extensive angioma Small angioma
Treatment No treatment Treatment No treatment
before seizures before seizures before seizures before seizures
Number 4 11 12 10
Epilepsy 3 (75%) 11 (100%) 8 (66%) 10 (100%)
—severe epilepsy 2 (50%) 9 (81.5%) 3 (25%) 4 (40%)
Normal development 1 (25%) 1 (9%) 8 (67%) 4 (40%)
Mental retardation 3 (75%) 10 (90%) 4 (33%) 6 (60%)
—Moderate 1 (25%) 3 (25%) 4 (33%) 6 (60%)
—Severe 2 (50%) 7 (64%) 0 0
Motor deficit 4 (100%) 8 (72.7%) 3 (25%) 3 (30%)
—Hemiplegia 1 2 0 0
—Moderate 0 1 0 1
—Mild 3 5 3 2
it is increased before the occurrence of the first
seizure12, 13. It may appear paradoxical to have a pro-
tective effect on cognitive functions from a compound
(phenobarbitone) known to affect cognitive function
when given in early life, particularly in brain damaged
individuals. We take this as an argument that the ben-
efit of protection against epilepsy outweighed the neg-
ative impact of the compound on developing cognitive
function. Lack of protective effect of anticonvulsant
treatment on motor function suggests that ischaemic
phenomena are mostly responsible for the motor
defects in SW disease. Indeed, the disease proves
to be progressive from very early in life, before the
age range of the development of cognitive functions,
and independently from epilepsy; rCBF decreases
within the first months of life, whether the patient
has experienced seizures or not13. Therefore, it seems
likely that motor functions are affected by ischaemic
events related to the size of the angioma, whereas the
cognitive impact is more likely linked to epilepsy.
Although no conclusion can be drawn regarding the
absolute benefit of prophylactic treatment in patients
with SW disease, better epileptic and cognitive out-
come in treated patients suggests that the hypothesis
of a benefit of prophylactic treatment is worth being
pursued, but that a prospective randomized study is
required to establish this benefit. Such a prospective
study should take in account the size of the angioma,
and include in endpoints, not only the occurrence
and severity of the epilepsy, but also the impact on
both cognitive and motor function. New techniques
of imaging (MRI with Gadolinium R© and SPECT)
may be helpful for an early diagnosis of the pial
angioma and for the choice of the children who could
be included.
Another difficult problem is the choice of the
appropriate medication. For this study, phenobarbitone
had been chosen because it was the only compound
available for the treatment of epilepsy in the newborn
and in infancy at the time the study was designed.
As a prophylaxis, the drug should have the same
requirements as for therapy: high efficacy, low
toxicity and good bioavailability, taking in account
the young age of the patients’. Phenobarbitone has
been shown to interfere with the development of
cognitive function14 and animal studies have shown
this negative impact to be even higher in cases
with brain lesions15. However, prophylactic use of
phenobarbitone was associated with a better outcome
than no prophylactic treatment in the present study.
Carbamazepine could be exhibited, but bioavailability
is unpredictable with this compound in the newborn
period, when protection is particularly important16,
and several cases of infantile spasms being triggered
by this compound, when given in early infancy, are
on record17–19. Phenytoin has prove ineffective and
difficult to administer in infancy, given its non-linear
pharmacokinetics20. Benzodiazepines could be used,
but the inefficacy is likely to be transient and the
ineffect on cognitive function would clearly be a major
concern. Vigabatrin is particularly effective in infantile
epilepsy21 but the issue of its causation of visual field
defect remains to be clarified, especially for a disease
that commonly affects visual fields22. Valproate could
be a candidate, although the effect in symptomatic
partial epilepsy seems to be moderate compared to that
of carbamazepine23.
CONCLUSIONS
Prophylactic treatment of epilepsy is a matter of
growing interest. This study shows that, even in a
highly selected group of patients with a high risk of
severe epilepsy, the benefits of prophylactic treatment
may be very difficult to demonstrate, and in SW would
need a number of patients randomized after imaging
had demonstrated the angioma and determined its
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size, and then followed prospectively. Such a trial
is feasible. It may however be as challenging as
to evaluate the benefits of prophylactic treatment
following head injury.
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